AbbVie to Invest $1.4 Billion in North Carolina Manufacturing Campus

• The campus will create 734 permanent jobs over four years and support more than 2,000 construction jobs, with construction starting in 2026 and completion expected by end of 2028
• AbbVie has committed over $2.2 billion in the past year for U.S. manufacturing projects, including a separate investment in February for pharmaceutical ingredient facilities in Illinois
• The North Carolina facility will manufacture injectable medicines for domestic and international markets, expanding the company's U.S. production capacity

AbbVie Announces $1.4 Billion North Carolina Manufacturing Investment

Key Investment Details:

AbbVie announced a $1.4 billion investment to build a new manufacturing campus in Durham, North Carolina, representing the drugmaker's largest single-site investment to date. The 185-acre facility will serve as the company's primary U.S. hub for injectable drug manufacturing, producing medicines for immune system diseases, cancer, and neurological disorders for domestic and international markets.

Timeline and Employment:

Construction is scheduled to begin in 2026 and complete by end of 2028, creating over 2,000 construction jobs during the build-out phase. AbbVie plans to hire 734 permanent employees over four years, including engineers, scientists, and manufacturing staff. The first phase includes manufacturing plants, laboratories, warehouses, office space, and employee facilities.

Strategic Context:

This investment is part of AbbVie's broader $100 billion commitment to U.S. research, development, and manufacturing over the next decade. The company has already committed over $2.2 billion to U.S. manufacturing projects in the past year alone. In February, AbbVie announced separate plans to build two active pharmaceutical ingredient facilities at its North Chicago, Illinois campus focusing on neuroscience and obesity medications.

Market Implications:

The significant capital deployment demonstrates AbbVie's confidence in expanding U.S. production capacity and strengthening its domestic pharmaceutical manufacturing footprint. This strategic investment positions the company to meet growing demand for injectable medications while reducing supply chain vulnerabilities, potentially benefiting long-term operational efficiency and market competitiveness in key therapeutic areas.